BioNTech’s Bet on BNT323 Intensifies as Restructuring and Pipeline Data Pave Way for Regulatory Milestone

The next few months will decide whether BioNTech can turn its sprawling oncology pipeline into a revenue-generating reality. With a regulatory filing for the antibody-drug conjugate BNT323 penciled in for this year, and a pivotal readout from its mRNA cancer vaccine BNT113 due in the fourth quarter, the German biotech is entering its most consequential period since the Covid vaccine windfall faded.

Trastuzumab pamirtecan, known as BNT323, targets HER2-expressing endometrial cancer and has shown an overall confirmed response rate of 47.9% across all HER2 levels in a Phase 2 trial. Among patients who had previously received immune checkpoint inhibitors, the response rate ticked up to 49.3%, with median progression-free survival reaching 8.1 months. The most striking data came from the subgroup with the highest HER2 expression (IHC 3+): more than 70% of those patients responded to treatment. While AstraZeneca and Daiichi Sankyo’s Enhertu won accelerated FDA approval in April 2024, it is limited to IHC 3+ patients. BNT323, by contrast, also demonstrated activity at lower HER2 levels – 33.9% in IHC 1+ and 40.4% in IHC 2+ – a population that currently has no approved HER2-directed therapy.

BioNTech and its partner DualityBio plan to submit the biologics license application to the FDA in 2026, subject to regulatory feedback. DualityBio has already filed for approval in China, and a confirmatory Phase 3 study is underway. The company presented additional data at the ASCO annual meeting in Chicago, including oral presentations on pumitamig and gotistobart, along with four posters covering ongoing studies. All told, BioNTech now has more than 25 Phase 2 and Phase 3 trials running, including 13 that are pivotal and potentially registration-enabling.

The science is advancing, but the financials tell a story of transition. First-quarter revenue dropped to €118.1 million from €182.8 million a year earlier, and the net loss widened to €531.9 million, or €2.10 per diluted share. Despite that, the balance sheet remains formidable: €16.8 billion in cash, cash equivalents and securities at the end of March. Management has confirmed full-year revenue guidance of €2.0 billion to €2.3 billion and a share buyback programme of up to $1 billion over twelve months.

Should investors sell immediately? Or is it worth buying BioNTech?

To fund its oncology ambitions, BioNTech is tearing down the infrastructure built for the Covid era. The company plans to exit sites in Idar-Oberstein, Marburg and Tübingen by the end of 2027, shut down its Singapore operations in the first quarter of 2027, and also close the CureVac facility. Up to 1,860 jobs are affected. The restructuring is expected to yield annual savings of €500 million by 2029, with the bulk of the freed-up cash redirected into the pipeline. Chief Financial Officer Ramón Zapata noted that from the end of 2026, all Covid vaccine supply will be handled through Pfizer and its existing capacity.

The market’s response to these moves has been mixed. UBS upgraded the stock from Neutral to Buy and raised its price target to $135 from $117, citing growing confidence in the late-stage oncology pipeline. Bernstein’s Jeffrey Walch struck a more reserved tone, initiating coverage with a Market Perform rating and a $96 target, arguing that shares have limited upside until clinical data translate into approvals and sales. The stock traded at €76.65 on Wednesday, roughly 25% below its 52-week high of €101.90 and down 7.1% year to date.

Leadership is also changing. Founders Ugur Sahin and Özlem Türeci plan to step back from their operational roles by the end of 2026. The incoming management team inherits a clear objective: secure approvals in ten cancer indications by 2030. With regulatory submissions and late-stage data readouts looming in the second half of this year, the next few months will do much to determine whether that target is realistic – and what the stock is truly worth.